PLA2G2A and heart disorder: Such sPLA2-interaction inhibitors could be proposed as alternatives to the bisphosphonates (Center et al., 2020; D'Oronzo et al., 2021), the actual treatment of choice for several osteoclast disorders, since bisphosphonates are contraindicated in older patients with kidney impairment or cardiac disease (Dos Santos Ferreira et al., 2017; Rogers et al., 2020; de Roij van Zuijdewijn et al., 2021).